Faster, better, stronger: Towards new antidepressant therapeutic strategies

European Journal of Pharmacology

Volumn 753, Issue , 2015, Pages 32-50

  O'Leary, Olivia F ^a,b   Dinan, Timothy G ^a,b   Cryan, John F ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Antidepressant; Depression

Indexed keywords

ACETYLCHOLINE; AMFEBUTAMONE; AMITIFADINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CX 157; ESCITALOPRAM; KETAMINE; LIAFENSINE; LIOTHYRONINE; LITHIUM; MOCLOBEMIDE; MONOAMINE OXIDASE A INHIBITOR; NEUROPEPTIDE; OLANZAPINE; OMEGA 3 FATTY ACID; OPIATE RECEPTOR; PROBIOTIC AGENT; QUETIAPINE; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPLE REUPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VILAZADONE; VORTIOXETINE;

ADJUVANT THERAPY; ARTICLE; BLOOD BRAIN BARRIER; DEPRESSION; DIET THERAPY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; DRUG WITHDRAWAL; DYSLIPIDEMIA; EPIGENETICS; HUMAN; IMMUNOMODULATION; METABOLIC DISORDER; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; OSTEOPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANIMAL; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG DEVELOPMENT; MOLECULARLY TARGETED THERAPY; PROCEDURES; TIME FACTOR;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG DISCOVERY; HUMANS; MOLECULAR TARGETED THERAPY; TIME FACTORS;

EID: 84922075404     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2014.07.046     Document Type: Article

References (444)

1. M. aan het Rot, K.A. Collins, J.W. Murrough, A.M. Perez, D.L. Reich, D.S. Charney, and S.J. Mathew Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression Biol. Psychiatry 67 2010 139 145
2. M. Aan Het Rot, C.A. Zarate, D.S. Charney, and S.J. Mathew Ketamine for depression: where do we go from here? Biol. Psychiatry 72 2012 537 547
3. M.P. Abbracchio, and G. Burnstock Purinoceptors - are there families of P2x and P2y purinoceptors Pharmacol. Ther. 64 1994 445 475
4. C.G. Abdallah, M. Fasula, B. Kelmendi, G. Sanacora, and R. Ostroff Rapid antidepressant effect of ketamine in the electroconvulsive therapy setting J. ECT 28 2012 157 161
5. M. Adli, D.L. Hollinde, T. Stamm, K. Wiethoff, M. Tsahuridu, J. Kirchheiner, A. Heinz, and M. Bauer Response to lithium augmentation in depression is associated with the glycogen synthase kinase 3-beta - 50T/C single nucleotide polymorphism Biol. Psychiatry 62 2007 1295 1302
6. G. Aguilera, and C. Rabadan-Diehl Vasopressinergic regulation of the hypothalamic-pituitary-adrenal axis: implications for stress adaptation Regul. Pept. 96 2000 23 29
7. S. Akhondzadeh, S. Jafari, F. Raisi, A.A. Nasehi, A. Ghoreishi, B. Salehi, S. Mohebbi-Rasa, M. Raznahan, and A. Kamalipour Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial Depress. Anxiety 26 2009 607 611
8. H. Akil, S.J. Evans, C.A. Turner, J. Perez, R.M. Myers, W.E. Bunney, E.G. Jones, and S.J. Watson The fibroblast growth factor family and mood disorders Novartis Found. Symp. 289 2008 94 96 (discussion 97-100, 193-105)
9. G. Alonso, V. Phan, I. Guillemain, M. Saunier, A. Legrand, M. Anoal, and T. Maurice Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system Neuroscience 97 2000 155 170
10. J.E. Alpert, D. Mischoulon, G.E. Rubenstein, K. Bottonari, A.A. Nierenberg, and M. Fava Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depression Ann. Clin. Psychiatry: Off. J. Am. Acad. Clin. Psychiatr. 14 2002 33 38
11. L.L. Altshuler, M. Bauer, M.A. Frye, M.J. Gitlin, J. Mintz, M.P. Szuba, K.L. Leight, and P.C. Whybrow Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature Am. J. Psychiatry 158 2001 1617 1622
12. I.M. Anderson SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability Depress. Anxiety 7 Suppl. 1 1998 S11 S17
13. I.M. Anderson Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability J. Affect. Disord. 58 2000 19 36
14. C. Andrade Augmentation of venlafaxine with bupropion: risks associated with a triple monoamine reuptake inhibition approach to partially responsive depression J. Clin. Psychiatry 74 2013 e119 121
15. J.T. Andreasen, E.O. Nielsen, J.K. Christensen, G.M. Olsen, D. Peters, N.R. Mirza, and J.P. Redrobe Subtype-selective nicotinic acetylcholine receptor agonists enhance the responsiveness to citalopram and reboxetine in the mouse forced swim test J. Psychopharmacol. 25 2011 1347 1356
16. J.T. Andreasen, G.M. Olsen, O. Wiborg, and J.P. Redrobe Antidepressant-like effects of nicotinic acetylcholine receptor antagonists, but not agonists, in the mouse forced swim and mouse tail suspension tests J. Psychopharmacol. 23 2009 797 804
17. J.T. Andreasen, J.P. Redrobe, E.O. Nielsen, J.K. Christensen, G.M. Olsen, and D. Peters A combined alpha7 nicotinic acetylcholine receptor agonist and monoamine reuptake inhibitor, NS9775, represents a novel profile with potential benefits in emotional and cognitive disturbances Neuropharmacology 73 2013 183 191
18. H. Anisman, and Z. Merali Anhedonic and anxiogenic effects of cytokine exposure Adv. Exp. Med. Biol. 461 1999 199 233
19. I. Antal-Zimanyi, and X. Khawaja The role of melanin-concentrating hormone in energy homeostasis and mood disorders J. Mol. Neurosci.: MN 39 2009 86 98
20. S. Arakawa, Y. Shirayama, Y. Fujita, T. Ishima, M. Horio, K. Muneoka, M. Iyo, and K. Hashimoto Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdala and no changes in BDNF levels in the hippocampus at baseline Pharmacol. Biochem. Behav. 100 2012 601 606
21. R. Aronson, H.J. Offman, R.T. Joffe, and C.D. Naylor Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis Arch. Gen. Psychiatry 53 1996 842 848
22. F. Artigas, A. Adell, and P. Celada Pindolol augmentation of antidepressant response Curr. Drug Targets 7 2006 139 147
23. F. Artigas, L. Romero, C. de Montigny, and P. Blier Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists Trends Neurosci. 19 1996 378 383
24. A.E. Autry, M. Adachi, E. Nosyreva, E.S. Na, M.F. Los, P.F. Cheng, E.T. Kavalali, and L.M. Monteggia NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses Nature 475 2011 91 95
25. F. Bacchi, A.A. Mathe, P. Jimenez, L. Stasi, R. Arban, P. Gerrard, and L. Caberlotto Anxiolytic-like effect of the selective Neuropeptide YY2 receptor antagonist BIIE0246 in the elevated plus-maze Peptides 27 2006 3202 3207
26. M.T. Bailey, S.E. Dowd, J.D. Galley, A.R. Hufnagle, R.G. Allen, and M. Lyte Exposure to a social stressor alters the structure of the intestinal microbiota: implications for stressor-induced immunomodulation Brain Behav. Immun. 25 2011 397 407
27. T.L. Bale, and W.W. Vale Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses J. Neurosci.: Off. J. Soc. Neurosci. 23 2003 5295 5301
28. T.L. Bale, and W.W. Vale CRF and CRF receptors: role in stress responsivity and other behaviors Annu. Rev. Pharmacol. Toxicol. 44 2004 525 557
29. M. Banasr, J.D. Rothstein, K. Tanaka, R.S. Duman, and G. Sanacora Role of glial glutamate transporter GLT1 (EAAT2) in the antidepressant action of riluzole and ceftriaxone Biol. Psychiatry 67 2010 236s
30. A.W. Bannon, J. Seda, M. Carmouche, J.M. Francis, M.H. Norman, B. Karbon, and M.L. McCaleb Behavioral characterization of neuropeptide Y knockout mice Brain Res. 868 2000 79 87
31. J. Barowsky, and T.L. Schwartz An evidence-based approach to augmentation and combination strategies for: treatment-resistant depression Psychiatry (Edgmont) 3 2006 42 61
32. A.M. Barr, J.W. Kinney, M.N. Hill, X. Lu, S. Biros, J. Rebek Jr., and T. Bartfai A novel, systemically active, selective galanin receptor type-3 ligand exhibits antidepressant-like activity in preclinical tests Neurosci. Lett. 405 2006 111 115
33. A.M. Basso, N.A. Bratcher, K.B. Gallagher, M.D. Cowart, C. Zhao, M. Sun, T.A. Esbenshade, M.E. Brune, G.B. Fox, M. Schmidt, C.A. Collins, A.J. Souers, R. Iyengar, A. Vasudevan, P.R. Kym, A.A. Hancock, and L.E. Rueter Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety Eur. J. Pharmacol. 540 2006 115 120
34. A. Baudry, S. Mouillet-Richard, B. Schneider, J.M. Launay, and O. Kellermann miR-16 targets the serotonin transporter: a new facet for adaptive responses to antidepressants Science 329 2010 1537 1541
35. M. Bauer, M. Adli, T. Bschor, M. Pilhatsch, A. Pfennig, J. Sasse, R. Schmid, and U. Lewitzka Lithiums emerging role in the treatment of refractory major depressive episodes: augmentation of antidepressants Neuropsychobiology 62 2010 36 42
36. M. Bauer, and S. Dopfmer Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies J. Clin. Psychopharmacol. 19 1999 427 434
37. M. Bauer, and P.C. Whybrow Thyroid hormone, neural tissue and mood modulation World J. Biol. Psychiatry: Off. J. World Fed. Soc. Biol. Psychiatry 2 2001 59 69
38. P. Baumann, R. Nil, A. Souche, S. Montaldi, D. Baettig, S. Lambert, C. Uehlinger, A. Kasas, M. Amey, and M. Jonzier-Perey A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation J. Clin. Psychopharmacol. 16 1996 307 314
39. P.M. Beardsley, J.L. Howard, K.L. Shelton, and F.I. Carroll Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats Psychopharmacology (Berl.) 183 2005 118 126
40. A.J. Bechtholt-Gompf, K.L. Smith, C.S. John, H.H. Kang, W.A. Carlezon Jr., B.M. Cohen, and D. Ongur CD-1 and Balb/cJ mice do not show enduring antidepressant-like effects of ketamine in tests of acute antidepressant efficacy Psychopharmacology (Berl.) 215 2011 689 695
41. I.V. Belozertseva, T. Kos, P. Popik, W. Danysz, and A.Y. Bespalov Antidepressant-like effects of mGluR1 and mGluR5 antagonists in the rat forced swim and the mouse tail suspension tests Eur. Neuropsychopharmacol. 17 2007 172 179
42. F. Benedetti, B. Barbini, E. Campori, M.C. Fulgosi, A. Pontiggia, and C. Colombo Sleep phase advance and lithium to sustain the antidepressant effect of total sleep deprivation in bipolar depression: new findings supporting the internal coincidence model? J. Psychiatr. Res. 35 2001 323 329
43. F. Benedetti, B. Barbini, C. Colombo, and E. Smeraldi Chronotherapeutics in a psychiatric ward Sleep Med. Rev. 11 2007 509 522
44. T. Benton, J. Staab, and D.L. Evans Medical co-morbidity in depressive disorders Ann. Clin. Psychiatry: Off. J. Am. Acad. Clin. Psychiatr. 19 2007 289 303
45. P. Bercik, E. Denou, J. Collins, W. Jackson, J. Lu, J. Jury, Y.K. Deng, P. Blennerhassett, J. Macri, K.D. McCoy, E.F. Verdu, and S.M. Collins The intestinal microbiota affect central levels of brain-derived neurotropic factor and behavior in mice Gastroenterology 141 2011 599 U701
46. R.M. Berman, A. Cappiello, A. Anand, D.A. Oren, G.R. Heninger, D.S. Charney, and J.H. Krystal Antidepressant effects of ketamine in depressed patients Biol. Psychiatry 47 2000 351 354
47. E.B. Binder The role of FKBP5, a co-chaperone of the glucocorticoid receptor in the pathogenesis and therapy of affective and anxiety disorders Psychoneuroendocrinology 34 Suppl. 1 2009 S186 S195
48. E.B. Binder, D. Salyakina, P. Lichtner, G.M. Wochnik, M. Ising, B. Putz, S. Papiol, S. Seaman, S. Lucae, M.A. Kohli, T. Nickel, H.E. Kunzel, B. Fuchs, M. Majer, A. Pfennig, N. Kern, J. Brunner, S. Modell, T. Baghai, T. Deiml, P. Zill, B. Bondy, R. Rupprecht, T. Messer, O. Kohnlein, H. Dabitz, T. Bruckl, N. Muller, H. Pfister, R. Lieb, J.C. Mueller, E. Lohmussaar, T.M. Strom, T. Bettecken, T. Meitinger, M. Uhr, T. Rein, F. Holsboer, and B. Muller-Myhsok Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment Nat. Genet. 36 2004 1319 1325
49. B. Binneman, D. Feltner, S. Kolluri, Y.J. Shi, R.L. Qiu, and T. Stiger A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression Am. J. Psychiatry 165 2008 617 620
50. W.V. Bobo, and R.C. Shelton Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression Expert Rev. Neurother. 10 2010 651 670
51. J.A. Bodkin, G.L. Zornberg, S.E. Lukas, and J.O. Cole Buprenorphine treatment of refractory depression J. Clin. Psychopharmacol. 15 1995 49 57
52. B. Borowsky, M.M. Durkin, K. Ogozalek, M.R. Marzabadi, J. DeLeon, R. Heurich, H. Lichtblau, Z. Shaposhnik, I. Daniewska, T.P. Blackburn, T.A. Branchek, C. Gerald, P.J. Vaysse, and C. Forray Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist Nat. Med. 8 2002 825 830
53. A.A. Boucher, J.C. Arnold, G.E. Hunt, A. Spiro, J. Spencer, C. Brown, I.S. McGregor, M.R. Bennett, and M. Kassiou Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test Neuroscience 189 2011 170 177
54. P. Brambilla, J. Perez, F. Barale, G. Schettini, and J.C. Soares GABAergic dysfunction in mood disorders Mol. Psychiatry 8 721-737 2003 715
55. J.A. Bravo, P. Forsythe, M.V. Chew, E. Escaravage, H.M. Savignac, T.G. Dinan, J. Bienenstock, and J.F. Cryan Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve Proc. Natl. Acad. Sci. USA 108 2011 16050 16055
56. G. Breen, B.T. Webb, A.W. Butler, E.J. van den Oord, F. Tozzi, N. Craddock, M. Gill, A. Korszun, W. Maier, L. Middleton, O. Mors, M.J. Owen, S. Cohen-Woods, J. Perry, N.W. Galwey, R. Upmanyu, I. Craig, C.M. Lewis, M. Ng, S. Brewster, M. Preisig, M. Rietschel, L. Jones, J. Knight, J. Rice, P. Muglia, A.E. Farmer, and P. McGuffin A genome-wide significant linkage for severe depression on chromosome 3: the depression network study Am. J. Psychiatry 168 2011 840 847
57. B. Breitenstein, S. Scheuer, H. Pfister, M. Uhr, S. Lucae, F. Holsboer, M. Ising, and T.M. Bruckl The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study CNS Spectr. 19 2014 165 175
58. M.E. Breuer, M.M. van Gaalen, W. Wernet, S.E. Claessens, R.S. Oosting, B. Behl, S.M. Korte, H. Schoemaker, G. Gross, B. Olivier, and L. Groenink SSR149415, a non-peptide vasopressin V1b receptor antagonist, has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model Naunyn Schmiedebergs Arch. Pharmacol. 379 2009 101 106
59. D.C. Broom, E.M. Jutkiewicz, J.E. Folk, J.R. Traynor, K.C. Rice, and J.H. Woods Nonpeptidic delta-opioid receptor agonists reduce immobility in the forced swim assay in rats Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 26 2002 744 755
60. C.A. Browne, and I. Lucki Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants Front. Pharmacol. 4 2013 161
61. A.W. Bruijnzeel kappa-Opioid receptor signaling and brain reward function Brain Res. Rev. 62 2009 127 146
62. A.R. Brunoni, M. Lopes, and F. Fregni A systematic review and meta-analysis of clinical studies on major depression and BDNF levels: implications for the role of neuroplasticity in depression Int. J. Neuropsychopharmacol. 11 2008 1169 1180
63. T.M. Buckley, and A.F. Schatzberg A pilot study of the phase angle between cortisol and melatonin in major depression - a potential biomarker? J. Psychiatr. Res. 44 2010 69 74
64. R. Bullock SGS-742 Novartis Curr. Opin. Investig. Drugs 6 2005 108 113
65. B.G. Bunney, and W.E. Bunney Rapid-acting antidepressant strategies: mechanisms of action Int. J. Neuropsychopharmacol. 15 2012 695 713
66. B.G. Bunney, and W.E. Bunney Mechanisms of rapid antidepressant effects of sleep deprivation therapy: clock genes and circadian rhythms Biol. Psychiatry 73 2013 1164 1171
67. G. Burnstock, B.B. Fredholm, and A. Verkhratsky Adenosine and ATP receptors in the brain Curr. Top. Med. Chem. 11 2011 973 1011
68. B.J. Caldarone, A. Harrist, M.A. Cleary, R.D. Beech, S.L. King, and M.R. Picciotto High-affinity nicotinic acetylcholine receptors are required for antidepressant effects of amitriptyline on behavior and hippocampal cell proliferation Biol. Psychiatry 56 2004 657 664
69. B. Campo, M. Kalinichev, N. Lambeng, M. El Yacoubi, I. Royer-Urios, M. Schneider, C. Legrand, D. Parron, F. Girard, A. Bessif, S. Poli, J.M. Vaugeois, E. Le Poul, and S. Celanire Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression J. Neurogenet. 25 2011 152 166
70. W.A. Carlezon Jr., C. Beguin, A.T. Knoll, and B.M. Cohen Kappa-opioid ligands in the study and treatment of mood disorders Pharmacol. Ther. 123 2009 334 343
71. G.V. Carr, D.A. Bangasser, T. Bethea, M. Young, R.J. Valentino, and I. Lucki Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 35 2010 752 763
72. A.F. Carvalho, J.L. Cavalcante, M.S. Castelo, and M.C. Lima Augmentation strategies for treatment-resistant depression: a literature review J. Clin. Pharm. Ther. 32 2007 415 428
73. M. Catena-DellOsso, A. Fagiolini, D. Marazziti, S. Baroni, and C. Bellantuono Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides Mini Rev. Med. Chem. 13 2013 2 10
74. P. Celada, A. Bortolozzi, and F. Artigas Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research CNS Drugs 27 2013 703 716
75. S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A. Pilc mGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants Neuropharmacology 66 2013 40 52
76. S. Chaki, T. Funakoshi, S. Hirota-Okuno, M. Nishiguchi, T. Shimazaki, M. Iijima, A.J. Grottick, K. Kanuma, K. Omodera, Y. Sekiguchi, S. Okuyama, T.A. Tran, G. Semple, and W. Thomsen Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists J. Pharmacol. Exp. Ther. 313 2005 831 839
77. S. Chaki, R. Yoshikawa, S. Hirota, T. Shimazaki, M. Maeda, N. Kawashima, T. Yoshimizu, A. Yasuhara, K. Sakagami, S. Okuyama, S. Nakanishi, and A. Nakazato MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity Neuropharmacology 46 2004 457 467
78. C.M. Chang, S. Sato, and C. Han Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression CNS Drugs 27 Suppl. 1 2013 S21 S27
79. M.M. Chang, and S.E. Leeman Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P J. Biol. Chem. 245 1970 4784 4790
80. E.H. Chartoff, M. Papadopoulou, M.L. MacDonald, A. Parsegian, D. Potter, C. Konradi, and W.A. Carlezon Desipramine reduces stress-activated dynorphin expression and CREB phosphorylation in NAc tissue Mol. Pharmacol. 75 2009 704 712
81. S. Chaviaras, P. Mak, D. Ralph, L. Krishnan, and J.H. Broadbear Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test Psychopharmacology (Berl.) 210 2010 35 43
82. G. Clarke, S. Grenham, P. Scully, P. Fitzgerald, R.D. Moloney, F. Shanahan, T.G. Dinan, and J.F. Cryan The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner Mol. Psychiatry 18 2013 666 673
83. G. Clarke, S.M. OMahony, J.F. Cryan, and T.G. Dinan Verapamil in treatment resistant depression: a role for the P-glycoprotein transporter? Hum. Psychopharmacol. 24 2009 217 223
84. R.L. Cole, C. Konradi, J. Douglass, and S.E. Hyman Neuronal adaptation to amphetamine and dopamine: molecular mechanisms of prodynorphin gene regulation in rat striatum Neuron 14 1995 813 823
85. K.R. Connolly, and M.E. Thase If at first you dont succeed a review of the evidence for antidepressant augmentation, combination and switching strategies Drugs 71 2011 43 64
86. K.R. Connolly, and M.E. Thase Emerging drugs for major depressive disorder Expert Opin. Emerg. Drugs 17 2012 105 126
87. B. Conti, R. Maier, A.M. Barr, M.C. Morale, X. Lu, P.P. Sanna, G. Bilbe, D. Hoyer, and T. Bartfai Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine Mol. Psychiatry 12 2007 167 189
88. R. Cooper-Kazaz, and B. Lerer Efficacy and safety of triiodothyronine supplementation in patients with major depressive disorder treated with specific serotonin reuptake inhibitors Int. J. Neuropsychopharmacol. 11 2008 685 699
89. A. Coppen, and J. Bailey Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo controlled trial J. Affect. Disord. 60 2000 121 130
90. B. Costall, and R.J. Naylor 5-HT3 receptors Curr. Drug Targets CNS Neurol. Disord. 3 2004 27 37
91. H.E. Covington 3rd, I. Maze, Q.C. LaPlant, V.F. Vialou, Y.N. Ohnishi, O. Berton, D.M. Fass, W. Renthal, A.J. Rush 3rd, E.Y. Wu, S. Ghose, V. Krishnan, S.J. Russo, C. Tamminga, S.J. Haggarty, and E.J. Nestler Antidepressant actions of histone deacetylase inhibitors J. Neurosci.: Off. J. Soc. Neurosci. 29 2009 11451 11460
92. P.E. Croarkin, P.A. Nakonezny, M.M. Husain, J.D. Port, T. Melton, B.D. Kennard, G.J. Emslie, F.A. Kozel, and Z.J. Daskalakis Evidence for pretreatment LICI deficits among depressed children and adolescents with nonresponse to fluoxetine Brain Stimul. 7 2014 243 251
93. N.A. Crossley, and M. Bauer Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials J. Clin. Psychiatry 68 2007 935 940
94. J.D. Croxtall, and L.J. Scott Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder CNS Drugs 24 2010 245 262
95. J.F. Cryan, and T.G. Dinan Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour Nat. Rev. Neurosci. 13 2012 701 712
96. J.F. Cryan, and K. Kaupmann Dont worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression Trends Pharmacol. Sci. 26 2005 36 43
97. J.F. Cryan, P.H. Kelly, H.C. Neijt, G. Sansig, P.J. Flor, and H. van Der Putten Antidepressant and anxiolytic-like effects in mice lacking the group III metabotropic glutamate receptor mGluR7 Eur. J. Neurosci. 17 2003 2409 2417
98. J.F. Cryan, and D.A. Slattery GABAB receptors and depression. Current status Adv. Pharmacol. 58 2010 427 451
99. E. Dailly, F. Chenu, C.E. Renard, and M. Bourin Dopamine, depression and antidepressants Fundam. Clin. Pharmacol. 18 2004 601 607
100. K.J. Davey, S.M. OMahony, H. Schellekens, O. OSullivan, J. Bienenstock, P.D. Cotter, T.G. Dinan, and J.F. Cryan Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters Psychopharmacology (Berl.) 221 2012 155 169
101. D.J. David, K.C. Klemenhagen, K.A. Holick, M.D. Saxe, I. Mendez, L. Santarelli, D.A. Craig, H. Zhong, C.J. Swanson, L.G. Hegde, X.I. Ping, D. Dong, M.R. Marzabadi, C.P. Gerald, and R. Hen Efficacy of the MCHR1 antagonist N-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}(4-piperidyl))-4-methylphenyl]-2-m ethylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis J. Pharmacol. Exp. Ther. 321 2007 237 248
102. O.L. de Klerk, A.T. Willemsen, M. Roosink, A.L. Bartels, N.H. Hendrikse, F.J. Bosker, and J.A. den Boer Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier Int. J. Neuropsychopharmacol. 12 2009 895 904
103. V.N. de Paiva, S.N. Lima, M.M. Fernandes, R. Soncini, C.A. Andrade, and A. Giusti-Paiva Prostaglandins mediate depressive-like behaviour induced by endotoxin in mice Behav. Brain Res. 215 2010 146 151
104. P.L. Delgado, D.S. Charney, L.H. Price, G.K. Aghajanian, H. Landis, and G.R. Heninger Serotonin function and the mechanism of antidepressant action - reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan Arch. Gen. Psychiatry 47 1990 411 418
105. P.L. Delgado, H.L. Miller, R.M. Salomon, J. Licinio, G.R. Heninger, A.J. Gelenberg, and D.S. Charney Monoamines and the mechanism of antidepressant action: effects of catecholamine depletion on mood of patients treated with antidepressants Psychopharmacol. Bull. 29 1993 389 396
106. P.L. Delgado, H.L. Miller, R.M. Salomon, J. Licinio, J.H. Krystal, F.A. Moreno, G.R. Heninger, and D.S. Charney Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action Biol. Psychiatry 46 1999 212 220
107. P.L. Delgado, L.H. Price, H.L. Miller, R.M. Salomon, J. Licinio, J.H. Krystal, G.R. Heninger, and D.S. Charney Rapid serotonin depletion as a provocative challenge test for patients with major depression - relevance to antidepressant action and the neurobiology of depression Psychopharmacol. Bull. 27 1991 321 330
108. L. Desbonnet, L. Garrett, G. Clarke, B. Kiely, J.F. Cryan, and T.G. Dinan Effects of the probiotic Bifidobacterium infantis in the maternal separation model of depression Neuroscience 170 2010 1179 1188
109. N. DiazGranados, L.A. Ibrahim, N.E. Brutsche, R. Ameli, I.D. Henter, D.A. Luckenbaugh, R. Machado-Vieira, and C.A. Zarate Jr. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-d-aspartate antagonist in patients with treatment-resistant major depressive disorder J. Clin. Psychiatry 71 2010 1605 1611
110. S.L. Dickson, E. Egecioglu, S. Landgren, K.P. Skibicka, J.A. Engel, and E. Jerlhag The role of the central ghrelin system in reward from food and chemical drugs Mol. Cell. Endocrinol. 340 2011 80 87
111. T.G. Dinan Inflammatory markers in depression Curr. Opin. Psychiatry 22 2009 32 36
112. T.G. Dinan, and J.F. Cryan Melancholic microbes: a link between gut microbiota and depression? Neurogastroenterol. Motil. 25 2013 713 719
113. T.G. Dinan, C. Stanton, and J.F. Cryan Psychobiotics: a novel class of psychotropic Biol. Psychiatry 74 2013 720 726
114. W.C. Drevets, and M.L. Furey Replication of scopolamines antidepressant efficacy in major depressive disorder: a randomized, placebo-controlled clinical trial Biol. Psychiatry 67 2010 432 438
115. W.C. Drevets, C.A. Zarate Jr., and M.L. Furey Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review Biol. Psychiatry 73 2013 1156 1163
116. K.G. du Jardin, J.B. Jensen, C. Sanchez, and A.L. Pehrson Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 24 2014 160 171
117. C.H. Duman, L. Schlesinger, R. Terwilliger, D.S. Russell, S.S. Newton, and R.S. Duman Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise Behav. Brain Res. 198 2009 366 371
118. R.S. Duman Neurobiology of stress, depression, and rapid acting antidepressants: remodeling synaptic connections Depress. Anxiety 31 4 2014 291 296
119. R.S. Duman, and L.M. Monteggia A neurotrophic model for stress-related mood disorders Biol. Psychiatry 59 2006 1116 1127
120. R.S. Duman, and B. Voleti Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents Trends Neurosci. 35 2012 47 56
121. V. Duric, M. Banasr, P. Licznerski, H.D. Schmidt, C.A. Stockmeier, A.A. Simen, S.S. Newton, and R.S. Duman A negative regulator of MAP kinase causes depressive behavior Nat. Med. 16 2010 1328 1332
122. Y. Dwivedi, H.S. Rizavi, R.R. Conley, and G.N. Pandey ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream Raf kinases Raf-1 and B-Raf Mol. Psychiatry 11 2006 86 98
123. Y. Dwivedi, H.S. Rizavi, R.C. Roberts, R.C. Conley, C.A. Tamminga, and G.N. Pandey Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects J. Neurochem. 77 2001 916 928
124. K. Ebner, S.B. Sartori, and N. Singewald Tachykinin receptors as therapeutic targets in stress-related disorders Curr. Pharm. Des. 15 2009 1647 1674
125. G.A. Eby, and K.L. Eby Rapid recovery from major depression using magnesium treatment Med. Hypotheses 67 2006 362 370
126. M. Eckert, B. Egenberger, F. Doring, and E. Wischmeyer TREK-1 isoforms generated by alternative translation initiation display different susceptibility to the antidepressant fluoxetine Neuropharmacology 61 2011 918 923
127. R.H. Ehrensing, A.J. Kastin, G.F. Wurzlow, G.F. Michell, and A.H. Mebane Improvement in major depression after low subcutaneous doses of MIF-1 J. Affect. Disord. 31 1994 227 233
128. T.B. Ejsing, and K. Linnet Influence of P-glycoprotein inhibition on the distribution of the tricyclic antidepressant nortriptyline over the blood-brain barrier Hum. Psychopharmacol. 20 2005 149 153
129. T. Eller, V. Vasar, J. Shlik, and E. Maron Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 445 450
130. K.A. Ellsworth, I. Moon, B.W. Eckloff, B.L. Fridley, G.D. Jenkins, A. Batzler, J.M. Biernacka, R. Abo, A. Brisbin, Y. Ji, S. Hebbring, E.D. Wieben, D.A. Mrazek, R.M. Weinshilboum, and L. Wang FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder Pharmacogenet. Genomics 23 2013 156 166
131. H.M. Emrich, P. Vogt, and A. Herz Possible antidepressive effects of opioids: action of buprenorphine Ann. N. Y. Acad. Sci. 398 1982 108 112
132. E. Engin, D. Treit, and C.T. Dickson Anxiolytic- and antidepressant-like properties of ketamine in behavioral and neurophysiological animal models Neuroscience 161 2009 359 369
133. M. Fava Diagnosis and definition of treatment-resistant depression Biol. Psychiatry 53 2003 649 659
134. M. Fava, J. Alpert, A. Nierenberg, I. Lagomasino, S. Sonawalla, J. Tedlow, J. Worthington, L. Baer, and J.F. Rosenbaum Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine J. Clin. Psychopharmacol. 22 2002 379 387
135. M. Fava, J.F. Rosenbaum, P.J. McGrath, J.W. Stewart, J.D. Amsterdam, and F.M. Quitkin Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study Am. J. Psychiatry 151 1994 1372 1374
136. J.P. Feighner, L. Sverdlov, J. Hlavka, G. Nicolau, K. Cartwright, and J.S. Freed Clinical effect of nemifitide, a novel pentapeptide antidepressant, in the treatment of severely depressed refractory patients Int. Clin. Psychopharmacol. 23 2008 29 35
137. J.P. Feighner, L. Sverdlov, G. Nicolau, H.B. Abajian, J. Hlavka, J.S. Freed, and G. Tonelli Jr. Clinical effectiveness of nemifitide, a novel pentapeptide antidepressant, in depressed outpatients: comparison of follow-up re-treatment with initial treatment Int. J. Neuropsychopharmacol. 6 2003 207 213
138. J.C. Felger, and F.E. Lotrich Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications Neuroscience 246 2013 199 229
139. D. Felice, O.F. OLeary, R.C. Pizzo, and J.F. Cryan Blockade of the GABA(B) receptor increases neurogenesis in the ventral but not dorsal adult hippocampus: relevance to antidepressant action Neuropharmacology 63 2012 1380 1388
140. B. Feng, J.B. Mills, R.E. Davidson, R.J. Mireles, J.S. Janiszewski, M.D. Troutman, and S.M. de Morais In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system Drug Metab. Dispos.: Biol. Fate Chem. 36 2008 268 275
141. D. Filliol, S. Ghozland, J. Chluba, M. Martin, H.W. Matthes, F. Simonin, K. Befort, C. Gaveriaux-Ruff, A. Dierich, M. LeMeur, O. Valverde, R. Maldonado, and B.L. Kieffer Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses Nat. Genet. 25 2000 195 200
142. J.A. Fishback, M.J. Robson, Y.T. Xu, and R.R. Matsumoto Sigma receptors: potential targets for a new class of antidepressant drug Pharmacol. Ther. 127 2010 271 282
143. T.E. Fitch, M.J. Benvenga, C.D. Jesudason, C. Zink, A.B. Vandergriff, M.M. Menezes, D.A. Schober, and L.M. Rorick-Kehn LSN2424100: a novel, potent orexin-2 receptor antagonist with selectivity over orexin-1 receptors and activity in an animal model predictive of antidepressant-like efficacy Front. Neurosci. 8 2014 5
144. J.A. Foster, and K.A.M. Neufeld Gut-brain: how the microbiome influences anxiety and depression Trends Neurosci. 36 2013 305 312
145. M. Frankowska, M. Filip, and E. Przegalinski Effects of GABAB receptor ligands in animal tests of depression and anxiety Pharmacol. Rep. 59 2007 645 655
146. N. Frasure-Smith, F. Lesperance, M.R. Irwin, C. Sauve, J. Lesperance, and P. Theroux Depression, C-reactive protein and two-year major adverse cardiac events in men after acute coronary syndromes Biol. Psychiatry 62 2007 302 308
147. M.P. Freeman Omega-3 fatty acids in major depressive disorder J. Clin. Psychiatry 70 Suppl. 5 2009 S7 S11
148. A. Frey, A. Lampert, K. Dietz, S. Striebich, C. Locher, O. Fedorenko, R. Mohle, J. Gallinat, F. Lang, and U.E. Lang Thyrotropin serum concentrations in healthy volunteers are associated with depression-related personality traits Neuropsychobiology 56 2007 123 126
149. W. Froestl, M. Gallagher, H. Jenkins, A. Madrid, T. Melcher, S. Teichman, C.G. Mondadori, and R. Pearlman SGS742: the first GABA(B) receptor antagonist in clinical trials Biochem. Pharmacol. 68 2004 1479 1487
150. M. Fujiwara-Sawada, T. Imanishi, A. Yoshida, and J. Baba Possible involvement of peripheral serotonin 5-HT3 receptors in fluvoxamine-induced emesis in Suncus murinus J. Pharm. Pharmacol. 55 2003 271 274
151. M.L. Furey, and W.C. Drevets Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial Arch. Gen. Psychiatry 63 2006 1121 1129
152. L.S. Garcia, C.M. Comim, S.S. Valvassori, G.Z. Reus, L. Stertz, F. Kapczinski, E.C. Gavioli, and J. Quevedo Ketamine treatment reverses behavioral and physiological alterations induced by chronic mild stress in rats Prog. Neuropsychopharmacol. Biol. Psychiatry 33 2009 450 455
153. D.R. Gehlert, K. Rasmussen, J. Shaw, X. Li, P. Ardayfio, L. Craft, T. Coskun, H.Y. Zhang, Y. Chen, and J.M. Witkin Preclinical evaluation of melanin-concentrating hormone receptor 1 antagonism for the treatment of obesity and depression J. Pharmacol. Exp. Ther. 329 2009 429 438
154. T.P. George, K.A. Sacco, J.C. Vessicchio, A.H. Weinberger, and R.D. Shytle Nicotinic antagonist augmentation of selective serotonin reuptake inhibitor-refractory major depressive disorder - a preliminary study J. Clin. Psychopharmacol. 28 2008 340 344
155. T.D. Geracioti Jr., L.L. Carpenter, M.J. Owens, D.G. Baker, N.N. Ekhator, P.S. Horn, J.R. Strawn, G. Sanacora, B. Kinkead, L.H. Price, and C.B. Nemeroff Elevated cerebrospinal fluid substance p concentrations in posttraumatic stress disorder and major depression Am. J. Psychiatry 163 2006 637 643
156. S. Ghose, M.K. Winter, K.E. McCarson, C.A. Tamminga, and S.J. Enna The GABA(B) receptor as a target for antidepressant drug action Br. J. Pharmacol. 162 2011 1 17
157. C. Giachino, M. Barz, J.S. Tchorz, M. Tome, M. Gassmann, J. Bischofberger, B. Bettler, and V. Taylor GABA suppresses neurogenesis in the adult hippocampus through GABAB receptors Development 141 2014 83 90
158. G. Gimpl, and F. Fahrenholz The oxytocin receptor system: structure, function, and regulation Physiol. Rev. 81 2001 629 683
159. S.S. Girdler, and R. Klatzkin Neurosteroids in the context of stress: implications for depressive disorders Pharmacol. Ther. 116 2007 125 139
160. A.S. Gonul, F. Akdeniz, F. Taneli, O. Donat, C. Eker, and S. Vahip Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients Eur. Arch. Psychiatry Clin. Neurosci. 255 2005 381 386
161. I. Goshen, T. Kreisel, O. Ben-Menachem-Zidon, T. Licht, J. Weidenfeld, T. Ben-Hur, and R. Yirmiya Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression Mol. Psychiatry 13 2008 717 728
162. T.D. Gould, H. Einat, R. Bhat, and H.K. Manji AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test Int. J. Neuropsychopharmacol. 7 2004 387 390
163. A. Govindarajan, B.S.S. Rao, D. Nair, M. Trinh, N. Mawjee, S. Tonegawa, and S. Chattarji Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects Proc. Natl. Acad. Sci. USA 103 2006 13208 13213
164. G. Griebel, S. Beeske, and S.M. Stahl The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies J. Clin. Psychiatry 73 2012 1403 1411
165. G. Griebel, J. Simiand, C. Serradeil-Le Gal, J. Wagnon, M. Pascal, B. Scatton, J.P. Maffrand, and P. Soubrie Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders Proc. Natl. Acad. Sci. USA 99 2002 6370 6375
166. G. Guidotti, F. Calabrese, C. Anacker, G. Racagni, C.M. Pariante, and M.A. Riva Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress: modulation by antidepressant treatment Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 38 2013 616 627
167. J.Y. Guo, C.Y. Li, Y.P. Ruan, M. Sun, X.L. Qi, B.S. Zhao, and F. Luo Chronic treatment with celecoxib reverses chronic unpredictable stress-induced depressive-like behavior via reducing cyclooxygenase-2 expression in rat brain Eur. J. Pharmacol. 612 2009 54 60
168. S.P. Hamilton A new lead from genetic studies in depressed siblings: assessing studies of chromosome 3 Am. J. Psychiatry 168 2011 783 789
169. H. Hashimoto, H. Onishi, S. Koide, T. Kai, and S. Yamagami Plasma neuropeptide Y in patients with major depressive disorder Neurosci. Lett. 216 1996 57 60
170. T. Hayashi, and T.P. Su An update on the development of drugs for neuropsychiatric disorders: focusing on the sigma 1 receptor ligand Expert Opin. Ther. Targets 12 2008 45 58
171. T. Hayashi, S.Y. Tsai, T. Mori, M. Fujimoto, and T.P. Su Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders Expert Opin. Ther. Targets 15 2011 557 577
172. P.B. Hedlund, S. Huitron-Resendiz, S.J. Henriksen, and J.G. Sutcliffe 5-HT7 receptor inhibition and inactivation induce antidepressantlike behavior and sleep pattern Biol. Psychiatry 58 2005 831 837
173. R.D. Heijtz, S.G. Wang, F. Anuar, Y. Qian, B. Bjorkholm, A. Samuelsson, M.L. Hibberd, H. Forssberg, and S. Pettersson Normal gut microbiota modulates brain development and behavior Proc. Natl. Acad. Sci. USA 108 2011 3047 3052
174. M. Heilig, S. Mcleod, M. Brot, S.C. Heinrichs, F. Menzaghi, G.F. Koob, and K.T. Britton Anxiolytic-like action of neuropeptide-Y - mediation by Y1 receptors in Amygdala, and dissociation from food-intake effects Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 8 1993 357 363
175. G.J. Hervieu Further insights into the neurobiology of melanin-concentrating hormone in energy and mood balances Expert Opin. Ther. Targets 10 2006 211 229
176. K.A. Hestad, S. Tonseth, C.D. Stoen, T. Ueland, and P. Aukrust Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy J. ECT 19 2003 183 188
177. C. Heurteaux, G. Lucas, N. Guy, M. El Yacoubi, S. Thummler, X.D. Peng, F. Noble, N. Blondeau, C. Widmann, M. Borsotto, G. Gobbi, J.M. Vaugeois, G. Debonnel, and M. Lazdunski Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype Nat. Neurosci. 9 2006 1134 1141
178. I. Hindmarch, and K. Hashimoto Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered Hum. Psychopharmacol. 25 2010 193 200
179. R.A. Hodgson, G.A. Higgins, D.H. Guthrie, S.X. Lu, A.J. Pond, D.E. Mullins, M.F. Guzzi, E.M. Parker, and G.B. Varty Comparison of the V1b antagonist, SSR149415, and the CRF1 antagonist, CP-154,526, in rodent models of anxiety and depression Pharmacol. Biochem. Behav. 86 2007 431 440
180. A. Holmes, M. Heilig, N.M. Rupniak, T. Steckler, and G. Griebel Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders Trends Pharmacol. Sci. 24 2003 580 588
181. B.A. Hoshaw, J.E. Malberg, and I. Lucki Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects Brain Res. 1037 2005 204 208
182. L. Ibrahim, N. Diaz Granados, L. Jolkovsky, N. Brutsche, D.A. Luckenbaugh, W.J. Herring, W.Z. Potter, and C.A. Zarate Jr. A randomized, placebo-controlled, crossover pilot trial of the oral selective NR2B antagonist MK-0657 in patients with treatment-resistant major depressive disorder J. Clin. Psychopharmacol. 32 2012 551 557
183. L. Ibrahim, N. Diazgranados, D.A. Luckenbaugh, R. Machado-Vieira, J. Baumann, A.G. Mallinger, and C.A. Zarate Jr. Rapid decrease in depressive symptoms with an N-methyl-d-aspartate antagonist in ECT-resistant major depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1155 1159
184. M. Iijima, and S. Chaki An arginine vasopressin V1b antagonist, SSR149415 elicits antidepressant-like effects in an olfactory bulbectomy model Prog. Neuropsychopharmacol. Biol. Psychiatry 31 2007 622 627
185. M. Iijima, K. Fukumoto, and S. Chaki Acute and sustained effects of a metabotropic glutamate 5 receptor antagonist in the novelty-suppressed feeding test Behav. Brain Res. 235 2012 287 292
186. S.A. Irwin, A. Iglewicz, R.A. Nelesen, J.Y. Lo, C.H. Carr, S.D. Romero, and L.S. Lloyd Daily oral ketamine for the treatment of depression and anxiety in patients receiving hospice care: a 28-day open-label proof-of-concept trial J. Palliat. Med. 16 2013 958 965
187. I.M. Jackson The thyroid axis and depression Thyroid: Off. J. Am. Thyroid Assoc. 8 1998 951 956
188. D.S. Janowsky, M.K. el-Yousef, J.M. Davis, and H.J. Sekerke A cholinergic-adrenergic hypothesis of mania and depression Lancet 2 1972 632 635
189. J.B. Jensen, K.G. du Jardin, D. Song, D. Budac, G. Smagin, C. Sanchez, and A.L. Pehrson Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 24 2014 148 159
190. R.S. Jope, and G.V. Johnson The glamour and gloom of glycogen synthase kinase-3 Trends Biochem. Sci. 29 2004 95 102
191. G. Juhasz, G. Hullam, N. Eszlari, X. Gonda, P. Antal, I.M. Anderson, T.G. Hokfelt, J.F. Deakin, and G. Bagdy Brain galanin system genes interact with life stresses in depression-related phenotypes Proc. Natl. Acad. Sci. USA 111 16 2014 E1666 E1673
192. E.M. Jutkiewicz The antidepressant-like effects of delta-opioid receptor agonists Mol. Interv. 6 2006 162 169
193. E.M. Jutkiewicz, K.C. Rice, J.R. Traynor, and J.H. Woods Separation of the convulsions and antidepressant-like effects produced by the delta-opioid agonist SNC80 in rats Psychopharmacology (Berl.) 182 2005 588 596
194. E.M. Jutkiewicz, and B.P. Roques Endogenous opioids as physiological antidepressants: complementary role of delta receptors and dopamine Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 37 2012 303 304
195. E.M. Jutkiewicz, S.K. Wood, H. Houshyar, L.W. Hsin, K.C. Rice, and J.H. Woods The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats Psychopharmacology (Berl.) 180 2005 215 223
196. F. Karege, G. Bondolfi, N. Gervasoni, M. Schwald, J.M. Aubry, and G. Bertschy Low brain-derived neurotrophic factor (BDNF) levels in serum of depressed patients probably results from lowered platelet BDNF release unrelated to platelet reactivity Biol. Psychiatry 57 2005 1068 1072
197. C.L. Katona, M.T. Abou-Saleh, D.A. Harrison, B.A. Nairac, D.R. Edwards, T. Lock, R.A. Burns, and M.M. Robertson Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine Br. J. Psychiatry: J. Ment. Sci. 166 1995 80 86
198. C.L. Katona, and C.P. Katona New generation multi-modal antidepressants: focus on vortioxetine for major depressive disorder Neuropsychiatr. Dis. Treat. 10 2014 349 354
199. M. Keller, S. Montgomery, W. Ball, M. Morrison, D. Snavely, G. Liu, R. Hargreaves, J. Hietala, C. Lines, K. Beebe, and S. Reines Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder Biol. Psychiatry 59 2006 216 223
200. R.C. Kessler, H.S. Akiskal, M. Ames, H. Birnbaum, P. Greenberg, R.M. Hirschfeld, R. Jin, K.R. Merikangas, G.E. Simon, and P.S. Wang Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers Am. J. Psychiatry 163 2006 1561 1568
201. R.C. Kessler, and E.J. Bromet The epidemiology of depression across cultures Annu. Rev. Public Health 34 2013 119 138
202. R.C. Kessler, K.R. Merikangas, and P.S. Wang Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century Annu. Rev. Clin. Psychol. 3 2007 137 158
203. R.C. Kessler, K.R. Merikangas, and P.S. Wang The prevalence and correlates of workplace depression in the national comorbidity survey replication J. Occup. Environ. Med./Am. Coll. Occup. Environ. Med. 50 2008 381 390
204. P.S. Klein, and D.A. Melton A molecular mechanism for the effect of lithium on development Proc. Natl. Acad. Sci. USA 93 1996 8455 8459
205. T.A. Klempan, A. Sequeira, L. Canetti, A. Lalovic, C. Ernst, J. Ffrench-Mullen, and G. Turecki Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression Mol. Psychiatry 14 2009 175 189
206. R.J. Knapp, R. Goldenberg, C. Shuck, A. Cecil, J. Watkins, C. Miller, G. Crites, and E. Malatynska Antidepressant activity of memory-enhancing drugs in the reduction of submissive behavior model Eur. J. Pharmacol. 440 2002 27 35
207. H. Koike, M. Iijima, and S. Chaki Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression Behav. Brain Res. 224 2011 107 111
208. J.W. Koo, and R.S. Duman IL-1 beta is an essential mediator of the antineurogenic and anhedonic effects of stress Proc. Natl. Acad. Sci. USA 105 2008 751 756
209. T.R. Kosten, C. Morgan, and T.A. Kosten Depressive symptoms during buprenorphine treatment of opioid abusers J. Subst. Abuse Treat. 7 1990 51 54
210. M.S. Kramer, N. Cutler, J. Feighner, R. Shrivastava, J. Carman, J.J. Sramek, S.A. Reines, G. Liu, D. Snavely, E. Wyatt-Knowles, J.J. Hale, S.G. Mills, M. MacCoss, C.J. Swain, T. Harrison, R.G. Hill, F. Hefti, E.M. Scolnick, M.A. Cascieri, G.G. Chicchi, S. Sadowski, A.R. Williams, L. Hewson, D. Smith, E.J. Carlson, R.J. Hargreaves, and N.M. Rupniak Distinct mechanism for antidepressant activity by blockade of central substance P receptors Science 281 1998 1640 1645
211. M.S. Kramer, A. Winokur, J. Kelsey, S.H. Preskorn, A.J. Rothschild, D. Snavely, K. Ghosh, W.A. Ball, S.A. Reines, D. Munjack, J.T. Apter, L. Cunningham, M. Kling, M. Bari, A. Getson, and Y. Lee Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 29 2004 385 392
212. L. Kranaster, J. Kammerer-Ciernioch, C. Hoyer, and A. Sartorius Clinically favourable effects of ketamine as an anaesthetic for electroconvulsive therapy: a retrospective study Eur. Arch. Psychiatry Clin. Neurosci. 261 2011 575 582
213. V. Krishnan, and E.J. Nestler The molecular neurobiology of depression Nature 455 2008 894 902
214. N. Kronfeld-Schor, and H. Einat Circadian rhythms and depression: human psychopathology and animal models Neuropharmacology 62 2012 101 114
215. J.H. Krystal, G. Sanacora, and R.S. Duman Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond Biol. Psychiatry 73 2013 1133 1141
216. M. Kubera, E. Obuchowicz, L. Goehler, J. Brzeszcz, and M. Maes In animal models, psychosocial stress-induced (neuro)inflammation, apoptosis and reduced neurogenesis are associated to the onset of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 744 759
217. E. Kuteeva, T. Hokfelt, T. Wardi, and S.O. Ogren Galanin, galanin receptor subtypes and depression-like behaviour Cell. Mol. Life Sci. 65 2008 1854 1863
218. E. Kuteeva, T. Wardi, L. Lundstrom, U. Sollenberg, U. Langel, T. Hokfelt, and S.O. Ogren Differential role of galanin receptors in the regulation of depression-like behavior and monoamine/stress-related genes at the cell body level Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 33 2008 2573 2585
219. L. Lanfumey, R. Mongeau, and M. Hamon Biological rhythms and melatonin in mood disorders and their treatments Pharmacol. Ther. 138 2013 176 184
220. S. Lanquillon, J.C. Krieg, U. Bening-Abu-Shach, and H. Vedder Cytokine production and treatment response in major depressive disorder Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 22 2000 370 379
221. K.A.B. Lapidus, C.F. Levitch, A.M. Perez, J.W. Brallier, M.K. Parides, L. Soleimani, A. Feder, D.V. Iosifescu, D.S. Charney, and J.W. Murrough A randomized controlled trial of intranasal ketamine in major depressive disorder Biol. Psychiatry 2014, http://dx.doi.org/10.1016/j.biopsych.2014.03.026, in press
222. H.Y. Lee, and Y.K. Kim Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants Neuropsychobiology 57 2008 194 199
223. M. Lekman, G. Laje, D. Charney, A.J. Rush, A.F. Wilson, A.J. Sorant, R. Lipsky, S.R. Wisniewski, H. Manji, F.J. McMahon, and S. Paddock The FKBP5-gene in depression and treatment response - an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR∗D) Cohort Biol. Psychiatry 63 2008 1103 1110
224. B. Leonard, and M. Maes Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression Neurosci. Biobehav. Rev. 36 2012 764 785
225. J. Levine, A. Cholestoy, and J. Zimmerman Possible antidepressant effect of minocycline Am. J. Psychiatry 153 1996 582
226. A.J. Levinson, P.B. Fitzgerald, G. Favalli, D.M. Blumberger, M. Daigle, and Z.J. Daskalakis Evidence of cortical inhibitory deficits in major depressive disorder Biol. Psychiatry 67 2010 458 464
227. M.I. Levy, Y. DeNigris, and K.L. Davis Rapid antidepressant activity of melanocyte-inhibiting factor: a clinical trial Biol. Psychiatry 17 1982 259 263
228. A.J. Lewy Depressive disorders may more commonly be related to circadian phase delays rather than advances: time will tell Sleep Med. 11 2010 117 118
229. N. Li, B. Lee, R.J. Liu, M. Banasr, J.M. Dwyer, M. Iwata, X.Y. Li, G. Aghajanian, and R.S. Duman mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists Science 329 2010 959 964
230. N. Li, R.J. Liu, J.M. Dwyer, M. Banasr, B. Lee, H. Son, X.Y. Li, G. Aghajanian, and R.S. Duman Glutamate N-methyl-d-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure Biol. Psychiatry 69 2011 754 761
231. X. Li, A.B. Need, M. Baez, and J.M. Witkin Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice J. Pharmacol. Exp. Ther. 319 2006 254 259
232. X. Li, J.P. Tizzano, K. Griffey, M. Clay, T. Lindstrom, and P. Skolnick Antidepressant-like actions of an AMPA receptor potentiator (LY392098) Neuropharmacology 40 2001 1028 1033
233. X.H. Li, and R.S. Jope Is Glycogen Synthase Kinase-3 a central modulator in mood regulation? Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 35 2010 2143 2154
234. X.H. Li, W. Zhu, M.S. Roh, A.B. Friedman, K. Rosborough, and R.S. Jope In vivo regulation of glycogen synthase kinase-3 beta (GSK3 beta) by serotonergic activity in mouse brain Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 29 2004 1426 1431
235. P.Y. Lin, and K.P. Su A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids J. Clin. Psychiatry 68 2007 1056 1061
236. J.S.O. Lindholm, H. Autio, L. Vesa, H. Antila, L. Lindemann, M.C. Hoener, P. Skolnick, T. Rantamaki, and E. Castren The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf(+/-) heterozygous null mice Neuropharmacology 62 2012 391 397
237. Y.J. Liou, T.J. Chen, S.J. Tsai, Y.W. Yu, C.Y. Cheng, and C.J. Hong Support for the involvement of the KCNK2 gene in major depressive disorder and response to antidepressant treatment Pharmacogenet. Genomics 19 2009 735 741
238. C. Louis, J. Stemmelin, D. Boulay, O. Bergis, C. Cohen, and G. Griebel Additional evidence for anxiolytic- and antidepressant-like activities of saredutant (SR48968), an antagonist at the neurokinin-2 receptor in various rodent-models Pharmacol. Biochem. Behav. 89 2008 36 45
239. M. Lutter, V. Krishnan, S.J. Russo, S. Jung, C.A. McClung, and E.J. Nestler Orexin signaling mediates the antidepressant-like effect of calorie restriction J. Neurosci.: Off. J. Soc. Neurosci. 28 2008 3071 3075
240. M. Lutter, I. Sakata, S. Osborne-Lawrence, S.A. Rovinsky, J.G. Anderson, S. Jung, S. Birnbaum, M. Yanagisawa, J.K. Elmquist, E.J. Nestler, and J.M. Zigman The orexigenic hormone ghrelin defends against depressive symptoms of chronic stress Nat. Neurosci. 11 2008 752 753
241. P.E. Lutz, and B.L. Kieffer Opioid receptors: distinct roles in mood disorders Trends Neurosci. 36 2013 195 206
242. G.M. MacQueen, K. Yucel, V.H. Taylor, K. Macdonald, and R. Joffe Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder Biol. Psychiatry 64 2008 880 883
243. S. Maeng, C.A. Zarate Jr., J. Du, R.J. Schloesser, J. McCammon, G. Chen, and H.K. Manji Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors Biol. Psychiatry 63 2008 349 352
244. M. Maes Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 664 675
245. M. Maes, Z. Fisar, M. Medina, G. Scapagnini, G. Nowak, and M. Berk New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates - Nrf2 activators and GSK-3 inhibitors Inflammopharmacology 20 2012 127 150
246. M. Maes, C. Song, and R. Yirmiya Targeting IL-1 in depression Expert Opin. Ther. Targets 16 2012 1097 1112
247. S.D. Mague, A.M. Pliakas, M.S. Todtenkopf, H.C. Tomasiewicz, Y. Zhang, W.C. Stevens Jr., R.M. Jones, P.S. Portoghese, and W.A. Carlezon Jr. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats J. Pharmacol. Exp. Ther. 305 2003 323 330
248. J. Maj, Z. Rogoz, G. Skuza, and H. Sowinska The effect of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in the forced swimming test Pol. J. Pharmacol. Pharm. 44 1992 337 346
249. J.E. Malberg, A.J. Eisch, E.J. Nestler, and R.S. Duman Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus J. Neurosci.: Off. J. Soc. Neurosci. 20 2000 9104 9110
250. H.K. Manji, W.C. Drevets, and D.S. Charney The cellular neurobiology of depression Nat. Med. 7 2001 541 547
251. R.S. Mansbach, E.N. Brooks, and Y.L. Chen Antidepressant-like effects of CP-154,526, a selective CRF1 receptor antagonist Eur. J. Pharmacol. 323 1997 21 26
252. D.M. Marks, C.U. Pae, and A.A. Patkar Triple reuptake inhibitors: the next generation of antidepressants Curr. Neuropharmacol. 6 2008 338 343
253. R.R. Matsumoto, Y.X. Yu, A. Mack, A. Coop, and J. Ash Selective sigma (sigma) receptor agonists produce antidepressant-like effects in mice FASEB J. 19 2005 A1543
254. C.A. McClung How might circadian rhythms control mood? Let me count the ways... Biol. Psychiatry 74 2013 242 249
255. B.S. McEwen Physiology and neurobiology of stress and adaptation: central role of the brain Physiol. Rev. 87 2007 873 904
256. I.M. Mcintyre, F.K. Judd, P.M. Marriott, G.D. Burrows, and T.R. Norman Plasma melatonin levels in affective states Int. J. Clin. Pharm. Res. 9 1989 159 164
257. D.P. McKernan, T.G. Dinan, and J.F. Cryan "Killing the Blues": a role for cellular suicide (apoptosis) in depression and the antidepressant response? Prog. Neurobiol. 88 2009 246 263
258. J.P. McLaughlin, M. Marton-Popovici, and C. Chavkin Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses J. Neurosci. 23 2003 5674 5683
259. J.L. Mendez-Andino, and J.A. Wos MCH-R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov. Today 12 2007 972 979
260. J. Mendlewicz, P. Kriwin, P. Oswald, D. Souery, S. Alboni, and N. Brunello Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study Int. Clin. Psychopharmacol. 21 2006 227 231
261. V. Micale, A. Tamburella, G.M. Leggio, C. Mazzola, V. Li Volsi, and F. Drago Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions Pharmacol. Biochem. Behav. 90 2008 463 469
262. M. Mieda, and T. Sakurai Overview of orexin/hypocretin system Prog. Brain Res. 198 2012 5 14
263. M.J. Millan Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application Pharmacol. Ther. 110 2006 135 370
264. Y.S. Mineur, E.B. Einstein, P.A. Seymour, J.W. Coe, B.T. ONeill, H. Rollema, and M.R. Picciotto alpha4beta2 nicotinic acetylcholine receptor partial agonists with low intrinsic efficacy have antidepressant-like properties Behav. Pharmacol. 22 2011 291 299
265. Y.S. Mineur, A. Obayemi, M.B. Wigestrand, G.M. Fote, C.A. Calarco, A.M. Li, and M.R. Picciotto Cholinergic signaling in the hippocampus regulates social stress resilience and anxiety- and depression-like behavior Proc. Natl. Acad. Sci. USA 110 2013 3573 3578
266. Y.S. Mineur, and M.R. Picciotto Nicotine receptors and depression: revisiting and revising the cholinergic hypothesis Trends Pharmacol. Sci. 31 2010 580 586
267. Y.S. Mineur, O. Somenzi, and M.R. Picciotto Cytisine, a partial agonist of high-affinity nicotinic acetylcholine receptors, has antidepressant-like properties in male C57BL/6J mice Neuropharmacology 52 2007 1256 1262
268. T. Miyaoka, R. Wake, M. Furuya, K. Liaury, M. Ieda, K. Kawakami, K. Tsuchie, M. Taki, K. Ishihara, T. Araki, and J. Horiguchi Minocycline as adjunctive therapy for patients with unipolar psychotic depression: an open-label study Prog. Neuropsychopharmacol. Biol. Psychiatry 37 2012 222 226
269. O. Mnie-Filali, C. Faure, L. Lambas-Senas, M. El Mansari, H. Belblidia, E. Gondard, A. Etievant, H. Scarna, A. Didier, A. Berod, P. Blier, and N. Haddjeri Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 36 2011 1275 1288
270. M. Molina-Hernandez, N.P. Tellez-Alcantara, J. Perez-Garcia, J.I. Olivera-Lopez, and M.T. Jaramillo-Jaimes Antidepressant-like actions of minocycline combined with several glutamate antagonists Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 380 386
271. M. Molina-Hernandez, N.P. Tellez-Alcantara, J. Perez-Garcia, J.I. Olivera-Lopez, and M.T. Jaramillo-Jaimes Desipramine or glutamate antagonists synergized the antidepressant-like actions of intra-nucleus accumbens infusions of minocycline in male Wistar rats Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 1660 1666
272. C. Mombereau, K. Kaupmann, W. Froestl, G. Sansig, H. van der Putten, and J.F. Cryan Genetic and pharmacological evidence of a role for GABA(B) receptors in the modulation of anxiety- and antidepressant-like behavior Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 29 2004 1050 1062
273. C. Mombereau, K. Kaupmann, M. Gassmann, B. Bettler, H. van der Putten, and J.F. Cryan Altered anxiety and depression-related behaviour in mice lacking GABAB(2) receptor subunits Neuroreport 16 2005 307 310
274. F. Montastruc, S. Scotto, I.R. Vaz, L.N. Guerra, A. Escudero, M. Sainz, T. Falomir, H. Bagheri, M.T. Herdeiro, M. Venegoni, J.L. Montastruc, and A. Carvajal Hepatotoxicity related to agomelatine and other new antidepressants: a case/noncase approach with information from the Portuguese, French, Spanish, and Italian pharmacovigilance systems J. Clin. Psychopharmacol 34 3 2014 327 330
275. P. Monteleone, V. Martiadis, and M. Maj Circadian rhythms and treatment implications in depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 1569 1574
276. S.A. Montgomery, J.P. Feighner, L. Sverdlov, R.K. Shrivastava, L.A. Cunningham, A. Kiev, J. Hlavka, and G. Tonelli Efficacy and safety of 30 mg/d and 45 mg/d nemifitide compared to placebo in major depressive disorder Int. J. Neuropsychopharmacol. 9 2006 517 528
277. F.A. Moreno, A.J. Gelenberg, G.R. Heninger, R.L. Potter, K.M. McKnight, J. Allen, A.P. Phillips, and P.L. Delgado Tryptophan depletion and depressive vulnerability Biol. Psychiatry 46 1999 498 505
278. A. Mork, L.P. Montezinho, S. Miller, C. Trippodi-Murphy, N. Plath, Y. Li, M. Gulinello, and C. Sanchez Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats Pharmacol. Biochem. Behav. 105 2013 41 50
279. N. Muller, M.J. Schwarz, S. Dehning, A. Douhe, A. Cerovecki, B. Goldstein-Muller, I. Spellmann, G. Hetzel, K. Maino, N. Kleindienst, H.J. Moller, V. Arolt, and M. Riedel The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine Mol. Psychiatry 11 2006 680 684
280. H. Murck, K. Held, M. Ziegenbein, H. Kunzel, F. Holsboer, and A. Steiger Intravenous administration of the neuropeptide galanin has fast antidepressant efficacy and affects the sleep EEG Psychoneuroendocrinology 29 2004 1205 1211
281. J.W. Murrough, and D.S. Charney Is there anything really novel on the antidepressant horizon? Curr. Psychiatry Rep. 14 2012 643 649
282. J.W. Murrough, D.V. Losifescu, L.C. Chang, R.K. Al Jurdi, C.E. Green, A.M. Perez, S. Lqbal, S. Pillemer, A. Foulkes, A. Shah, D.S. Charney, and S.J. Mathew Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial Am. J. Psychiatry 170 2013 1134 1142
283. J.W. Murrough, A.M. Perez, S. Pillemer, J. Stern, M.K. Parides, M. aan het Rot, K.A. Collins, S.J. Mathew, D.S. Charney, and D.V. Iosifescu Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression Biol. Psychiatry 74 2013 250 256
284. R. Mychasiuk, R. Gibb, and B. Kolb Prenatal stress alters dendritic morphology and synaptic connectivity in the prefrontal cortex and hippocampus of developing offspring Synapse 66 2012 308 314
285. Y. Nakagawa, A. Sasaki, and T. Takashima The GABA(B) receptor antagonist CGP36742 improves learned helplessness in rats Eur. J. Pharmacol. 381 1999 1 7
286. M. Nakajima, A. Inui, A. Asakawa, K. Momose, N. Ueno, A. Teranishi, S. Baba, and M. Kasuga Neuropeptide Y produces anxiety via Y2-type receptors Peptides 19 1998 359 363
287. M. Naughton, G. Clarke, O.F. OLeary, J.F. Cryan, and T.G. Dinan A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action J. Affect. Disord. 156 2014 24 35
288. C.B. Nemeroff, H.S. Mayberg, S.E. Krahl, J. McNamara, A. Frazer, T.R. Henry, M.S. George, D.S. Charney, and S.K. Brannan VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 31 2006 1345 1355
289. B. Nemets, Y. Osher, and R.H. Belmaker Omega-3 fatty acids and augmentation strategies in treating resistant depression Essent. Psychopharmacol. 6 2004 59 64
290. E.J. Nestler, and W.A. Carlezon Jr. The mesolimbic dopamine reward circuit in depression Biol. Psychiatry 59 2006 1151 1159
291. S.S. Newton, J. Thome, T.L. Wallace, Y. Shirayama, L. Schlesinger, N. Sakai, J.H. Chen, R. Neve, E.J. Nestler, and R.S. Duman Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect J. Neurosci. 22 2002 10883 10890
292. D.M. Nielsen, G.J. Carey, and L.H. Gold Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice Eur. J. Pharmacol. 499 2004 135 146
293. A. Nieoullon, and A. Coquerel Dopamine: a key regulator to adapt action, emotion, motivation and cognition Curr. Opin. Neurol. 16 Suppl. 2 2003 S3 S9
294. M. Nollet, P. Gaillard, F. Minier, A. Tanti, C. Belzung, and S. Leman Activation of orexin neurons in dorsomedial/perifornical hypothalamus and antidepressant reversal in a rodent model of depression Neuropharmacology 61 2011 336 346
295. M. Nollet, P. Gaillard, A. Tanti, V. Girault, C. Belzung, and S. Leman Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 37 2012 2210 2221
296. R.A. North Molecular physiology of P2X receptors Physiol. Rev. 82 2002 1013 1067
297. G. Nowak, A. Partyka, A. Palucha, B. Szewczyk, J.M. Wieronska, M. Dybala, M. Metz, T. Librowski, W. Froestl, M. Papp, and A. Pilc Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents Br. J. Pharmacol. 149 2006 581 590
298. F.E. OBrien, G. Clarke, P. Fitzgerald, T.G. Dinan, B.T. Griffin, and J.F. Cryan Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats Br. J. Pharmacol. 166 2012 1333 1343
299. F.E. OBrien, T.G. Dinan, B.T. Griffin, and J.F. Cryan Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings Br. J. Pharmacol. 165 2012 289 312
300. F.E. OBrien, R.M. OConnor, G. Clarke, T.G. Dinan, B.T. Griffin, and J.F. Cryan P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 38 2013 2209 2219
301. S.M. OBrien, P. Scully, P. Fitzgerald, L.V. Scott, and T.G. Dinan Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy J. Psychiatr. Res. 41 2007 326 331
302. W.T. OBrien, A.D. Harper, F. Jove, J.R. Woodgett, S. Maretto, S. Piccolo, and P.S. Klein Glycogen synthase kinase-3 beta haploinsufficiency mimics the behavioral and molecular effects of lithium J. Neurosci. 24 2004 6791 6798
303. R.M. OConnor, and J.F. Cryan The effects of mGlu(7) receptor modulation in behavioural models sensitive to antidepressant action in two mouse strains Behav. Pharmacol. 24 2013 105 113
304. R.M. OConnor, T.G. Dinan, and J.F. Cryan Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression Mol. Psychiatry 17 2012 359 376
305. R.M. OConnor, B.C. Finger, P.J. Flor, and J.F. Cryan Metabotropic glutamate receptor 7: at the interface of cognition and emotion Eur. J. Pharmacol. 639 2010 123 131
306. R.M. OConnor, S. Grenham, T.G. Dinan, and J.F. Cryan microRNAs as novel antidepressant targets: converging effects of ketamine and electroconvulsive shock therapy in the rat hippocampus Int. J. Neuropsychopharmacol. 16 2013 1885 1892
307. O.F. OLeary, and E. Castren Neurotrophic factors and antidepressant action: recent advances J.F. Cryan, B.E. Leonard, Depression: From Psychopathology to Pharmacotherapy 199-223 2010 Karger Basel pp
308. O.F. OLeary, F.E. OBrien, R.M. OConnor, and J.F. Cryan Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man Pharmacol. Biochem. Behav 123 2013 55 76
309. O.F. OLeary, S. Zandy, T.G. Dinan, and J.F. Cryan Lithium augmentation of the effects of desipramine in a mouse model of treatment-resistant depression: a role for hippocampal cell proliferation Neuroscience 228 2013 36 46
310. S.M. OMahony, J.R. Marchesi, P. Scully, C. Codling, A.M. Ceolho, E.M. Quigley, J.F. Cryan, and T.G. Dinan Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses Biol. Psychiatry 65 2009 263 267
311. N. Okamoto, T. Nakai, K. Sakamoto, Y. Nagafusa, T. Higuchi, and T. Nishikawa Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression comparing ketamine and propofol anesthesia J. ECT 26 2010 223 227
312. T. Okamoto, R. Yoshimura, A. Ikenouchi-Sugita, H. Hori, W. Umene-Nakano, Y. Inoue, N. Ueda, and J. Nakamura Efficacy of electroconvulsive therapy is associated with changing blood levels of homovanillic acid and brain-derived neurotrophic factor (BDNF) in refractory depressed patients: a pilot study Prog. Neuropsychopharmacol. Biol. Psychiatry 32 2008 1185 1190
313. K.T. Ota, R.J. Liu, B. Voleti, J.G. Maldonado-Aviles, V. Duric, M. Iwata, S. Dutheil, C. Duman, S. Boikess, D.A. Lewis, C.A. Stockmeier, R.J. DiLeone, C. Rex, G.K. Aghajanian, and R.S. Duman REDD1 is essential for stress-induced synaptic loss and depressive behavior Nat. Med. 20 5 2014 531 535
314. D.H. Overstreet, V.M. Naimoli, and G. Griebel Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression Pharmacol. Biochem. Behav. 96 2010 206 210
315. R.K. Owenby, L.T. Brown, and J.N. Brown Use of risperidone as augmentation treatment for major depressive disorder Ann. Pharmacother. 45 2011 95 100
316. C.U. Pae, D.M. Marks, C. Han, and A.A. Patkar Does minocycline have antidepressant effect? Biomed. Pharmacother. Biomed. Pharmacother. 62 2008 308 311
317. M.E. Page, J.F. Cryan, A. Sullivan, A. Dalvi, B. Saucy, D.R. Manning, and I. Lucki Behavioral and neurochemical effects of 5-(4-[4-(5-cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist J. Pharmacol. Exp. Ther. 302 2002 1220 1227
318. A. Palucha-Poniewiera, and A. Pilc Involvement of mGlu5 and NMDA receptors in the antidepressant-like effect of acamprosate in the tail suspension test Prog. Neuropsychopharmacol. Biol. Psychiatry 39 2012 102 106
319. A. Palucha-Poniewiera, J.M. Wieronska, P. Branski, K. Stachowicz, S. Chaki, and A. Pilc On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039 Psychopharmacology (Berl.) 212 2010 523 535
320. A. Palucha, K. Klak, P. Branski, H. van der Putten, P.J. Flor, and A. Pilc Activation of the mGlu7 receptor elicits antidepressant-like effects in mice Psychopharmacology (Berl.) 194 2007 555 562
321. G.I. Papakostas, and M. Fava A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder Can. J. Psychiatry - Rev. Can. Psychiatr. 51 2006 783 790
322. G.I. Papakostas, R.C. Shelton, J.M. Zajecka, B. Etemad, K. Rickels, A. Clain, L. Baer, E.D. Dalton, G.R. Sacco, D. Schoenfeld, M. Pencina, A. Meisner, T. Bottiglieri, E. Nelson, D. Mischoulon, J.E. Alpert, J.G. Barbee, S. Zisook, and M. Fava L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials Am. J. Psychiatry 169 2012 1267 1274
323. M. Papp, and E. Moryl Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression Eur. J. Pharmacol. 263 1994 1 7
324. C.M. Pariante, and A.H. Miller Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment Biol. Psychiatry 49 2001 391 404
325. A.J. Park, J. Collins, P.A. Blennerhassett, J.E. Ghia, E.F. Verdu, P. Bercik, and S.M. Collins Altered colonic function and microbiota profile in a mouse model of chronic depression Neurogastroenterol. Motil.: Off. J. Eur. Gastrointest. Motil. Soc. 25 2013 733-e575
326. V.S. Pereira, P.C. Casarotto, V.A. Hiroaki-Sato, A.G. Sartim, F.S. Guimaraes, and S.R. Joca Antidepressant- and anticompulsive-like effects of purinergic receptor blockade: involvement of nitric oxide Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol. 23 2013 1769 1778
327. M. Perello, and J.M. Zigman The role of ghrelin in reward-based eating Biol. Psychiatry 72 2012 347 353
328. M.L. Pergadia, A.L. Glowinski, N.R. Wray, A. Agrawal, S.F. Saccone, A. Loukola, U. Broms, T. Korhonen, B.W. Penninx, J.D. Grant, E.C. Nelson, A.K. Henders, A.J. Schrage, Y.L. Chou, K. Keskitalo-Vuokko, Q. Zhu, S.D. Gordon, J.M. Vink, E.J. de Geus, S. Macgregor, J.Z. Liu, G. Willemsen, S.E. Medland, D.I. Boomsma, G.W. Montgomery, J.P. Rice, A.M. Goate, A.C. Heath, J. Kaprio, N.G. Martin, and P.A. Madden A 3p26-3p25 genetic linkage finding for DSM-IV major depression in heavy smoking families Am. J. Psychiatry 168 2011 848 852
329. R.H. Perlis, P. Moorjani, J. Fagerness, S. Purcell, M.H. Trivedi, M. Fava, A.J. Rush, and J.W. Smoller Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(∗)D study Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 33 2008 2810 2819
330. N.S. Philip, L.L. Carpenter, A.R. Tyrka, and L.H. Price Augmentation of antidepressants with atypical antipsychotics: a review of the current literature J. Psychiatr. Pract. 14 2008 34 44
331. N.S. Philip, L.L. Carpenter, A.R. Tyrka, and L.H. Price Nicotinic acetylcholine receptors and depression: a review of the preclinical and clinical literature Psychopharmacology (Berl.) 212 2010 1 12
332. N.S. Philip, L.L. Carpenter, A.R. Tyrka, and L.H. Price The nicotinic acetylcholine receptor as a target for antidepressant drug development Sci. World J. 2012 2012 104105
333. N.S. Philip, L.L. Carpenter, A.R. Tyrka, L.B. Whiteley, and L.H. Price Varenicline augmentation in depressed smokers: an 8-week, open-label study J. Clin. Psychiatry 70 2009 1026 1031
334. A. Pilc, and G. Nowak GABAergic hypotheses of anxiety and depression: focus on GABA-B receptors Drugs Today (Barc.) 41 2005 755 766
335. A. Pilc, J.M. Wieronska, and P. Skolnick Glutamate-based antidepressants: preclinical psychopharmacology Biol. Psychiatry 73 2013 1125 1132
336. A.M. Pliakas, R.R. Carlson, R.L. Neve, C. Konradi, E.J. Nestler, and W.A. Carlezon Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens J. Neurosci. 21 2001 7397 7403
337. S.H. Preskorn, B. Baker, S. Kolluri, F.S. Menniti, M. Krams, and J.W. Landen An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-d-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder J. Clin. Psychopharmacol. 28 2008 631 637
338. R.B. Price, M.K. Nock, D.S. Charney, and S.J. Mathew Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression Biol. Psychiatry 66 2009 522 526
339. E. Przegalinski, E. Tatarczynska, A. DerenWesolek, and E. ChojnackaWojcik Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist Neuropharmacology 36 1997 31 37
340. J.C. Quirk, and E.S. Nisenbaum LY404187: a novel positive allosteric modulator of AMPA receptors CNS Drug Rev. 8 2002 255 282
341. R.L. Rabenstein, B.J. Caldarone, and M.R. Picciotto The nicotinic antagonist mecamylamine has antidepressant-like effects in wild-type but not beta 2- or alpha 7-nicotinic acetylcholine receptor subunit knockout mice Psychopharmacology (Berl.) 189 2006 395 401
342. C.L. Raison, R.E. Rutherford, B.J. Woolwine, C. Shuo, P. Schettler, D.F. Drake, E. Haroon, and A.H. Miller A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers JAMA Psychiatry 70 2013 31 41
343. R. Rajkumar, and R. Mahesh The auspicious role of the 5-HT3 receptor in depression: a probable neuronal target? J. Psychopharmacol. 24 2010 455 469
344. S. Ramachandran, U.B. Chu, T.A. Mavlyutov, A. Pal, S. Pyne, and A.E. Ruoho The sigma1 receptor interacts with N-alkyl amines and endogenous sphingolipids Eur. J. Pharmacol. 609 2009 19 26
345. R. Ramamoorthy, M. Radhakrishnan, and M. Borah Antidepressant-like effects of serotonin type-3 antagonist, ondansetron: an investigation in behaviour-based rodent models Behav. Pharmacol. 19 2008 29 40
346. E. Ratti, K. Bellew, P. Bettica, H. Bryson, S. Zamuner, G. Archer, L. Squassante, A. Bye, D. Trist, K.R. Krishnan, and S. Fernandes Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder J. Clin. Psychopharmacol. 31 2011 727 733
347. J.A. Reinhold, L.A. Mandos, F.W. Lohoff, and K. Rickels Evidence for the use of vilazodone in the treatment of major depressive disorder Expert Opin. Pharmacother. 13 2012 2215 2224
348. A. Rinaldi, S. Vincenti, F. De Vito, I. Bozzoni, A. Oliverio, C. Presutti, P. Fragapane, and A. Mele Stress induces region specific alterations in microRNAs expression in mice Behav. Brain Res. 208 2010 265 269
349. R. Risinger, Z. Bhagwagar, F. Luo, M. Cahir, L. Miler, A.E. Mendonza, J.H. Meyer, M. Zheng, and W. Hayes Evaluation of safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-820836 in healthy subjects: a placebo-controlled, ascending single-dose study Psychopharmacology (Berl.) 2013
350. H. Rollema, V. Guanowsky, Y.S. Mineur, A. Shrikhande, J.W. Coe, P.A. Seymour, and M.R. Picciotto Varenicline has antidepressant-like activity in the forced swim test and augments sertralines effect Eur. J. Pharmacol. 605 2009 114 116
351. A.J. Rush, D. Warden, S.R. Wisniewski, M. Fava, M.H. Trivedi, B.N. Gaynes, and A.A. Nierenberg STAR∗D: revising conventional wisdom CNS Drugs 23 2009 627 647
352. B.R. Rutherford, and S.P. Roose A model of placebo response in antidepressant clinical trials Am. J. Psychiatry 170 2013 723 733
353. T. Saarelainen, P. Hendolin, G. Lucas, E. Koponen, M. Sairanen, E. MacDonald, K. Agerman, A. Haapasalo, H. Nawa, R. Aloyz, P. Ernfors, and E. Castren Activation of the TrkB neurotrophin receptor is induced by antidepressant drugs and is required for antidepressant-induced behavioral effects J. Neurosci. 23 2003 349 357
354. M.N. Sabbagh Drug development for Alzheimers disease: where are we now and where are we headed? Am. J. Geriatr. Pharmacother. 7 2009 167 185
355. V. Sabino, P. Cottone, S.L. Parylak, L. Steardo, and E.P. Zorrilla Sigma-1 receptor knockout mice display a depressive-like phenotype Behav. Brain Res. 198 2009 472 476
356. A. Sahay, and R. Hen Adult hippocampal neurogenesis in depression Nat. Neurosci. 10 2007 1110 1115
357. M. Sairanen, G. Lucas, P. Ernfors, M. Castren, and E. Castren Brain-derived neurotrophic factor and antidepressant drugs have different but coordinated effects on neuronal turnover, proliferation, and survival in the adult dentate gyrus J. Neurosci. 25 2005 1089 1094
358. A. Saitoh, Y. Kimura, T. Suzuki, K. Kawai, H. Nagase, and J. Kamei Potential anxiolytic and antidepressant-like activities of SNC80, a selective delta-opioid agonist, in behavioral models in rodents J. Pharmacol. Sci. 95 2004 374 380
359. A. Saitoh, A. Sugiyama, T. Nemoto, H. Fujii, K. Wada, J. Oka, H. Nagase, and M. Yamada The novel delta opioid receptor agonist KNT-127 produces antidepressant-like and antinociceptive effects in mice without producing convulsions Behav. Brain Res. 223 2011 271 279
360. B. Sakic, J. Gauldie, J.A. Denburg, and H. Szechtman Behavioral effects of infection with IL-6 adenovector Brain Behav. Immun. 15 2001 25 42
361. J.D. Salamone, and M. Correa The mysterious motivational functions of mesolimbic dopamine Neuron 76 2012 470 485
362. G. Sanacora, and M. Banasr From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders Biol. Psychiatry 73 2013 1172 1179
363. G. Sanacora, S.F. Kendell, Y. Levin, A.A. Simen, L.R. Fenton, V. Coric, and J.H. Krystal Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms Biol. Psychiatry 61 2007 822 825
364. L. Santarelli, M. Saxe, C. Gross, A. Surget, F. Battaglia, S. Dulawa, N. Weisstaub, J. Lee, R. Duman, O. Arancio, C. Belzung, and R. Hen Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants Science 301 2003 805 809
365. J.E. Sarginson, L.C. Lazzeroni, H.S. Ryan, A.F. Schatzberg, and G.M. Murphy FKBP5 polymorphisms and antidepressant response in geriatric depression Am. J. Med. Genet. B 153B 2010 554 560
366. E. Saus, V. Soria, G. Escaramis, F. Vivarelli, J.M. Crespo, B. Kagerbauer, J.M. Menchon, M. Urretavizcaya, M. Gratacos, and X. Estivill Genetic variants and abnormal processing of pre-miR-182, a circadian clock modulator, in major depression patients with late insomnia Hum. Mol. Genet. 19 2010 4017 4025
367. J. Savitz, and W.C. Drevets Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide Neurosci. Biobehav. Rev. 33 2009 699 771
368. H. Schellekens, T.G. Dinan, and J.F. Cryan Ghrelin at the interface of obesity and reward Obesity 91 2013 285 323
369. H. Schellekens, B.C. Finger, T.G. Dinan, and J.F. Cryan Ghrelin signalling and obesity: at the interface of stress, mood and food reward Pharmacol. Ther. 135 2012 316 326
370. F.A. Schroeder, C.L. Lin, W.E. Crusio, and S. Akbarian Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse Biol. Psychiatry 62 2007 55 64
371. C. Schule, T.C. Baghai, D. Eser, and R. Rupprecht Hypothalamic-pituitary-adrenocortical system dysregulation and new treatment strategies in depression Expert Rev. Neurother. 9 2009 1005 1019
372. S. Sen, R. Duman, and G. Sanacora Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications Biol. Psychiatry 64 2008 527 532
373. R.M. Shansky, and J.H. Morrison Stress-induced dendritic remodeling in the medial prefrontal cortex: effects of circuit, hormones and rest Brain Res. 1293 2009 108 113
374. Y.I. Sheline, M.H. Gado, and H.C. Kraemer Untreated depression and hippocampal volume loss Am. J. Psychiatry 160 2003 1516 1518
375. E. Shimizu, K. Hashimoto, N. Okamura, K. Koike, N. Komatsu, C. Kumakiri, M. Nakazato, H. Watanabe, N. Shinoda, S. Okada, and M. Iyo Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants Biol. Psychiatry 54 2003 70 75
376. Y. Shirayama, A.C.H. Chen, S. Nakagawa, D.S. Russell, and R.S. Duman Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression J. Neurosci. 22 2002 3251 3261
377. Y. Shirayama, H. Ishida, M. Iwata, G.I. Hazama, R. Kawahara, and R.S. Duman Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects J. Neurochem. 90 2004 1258 1268
378. S.I. Shyn, J. Shi, J.B. Kraft, J.B. Potash, J.A. Knowles, M.M. Weissman, H.A. Garriock, J.S. Yokoyama, P.J. McGrath, E.J. Peters, W.A. Scheftner, W. Coryell, W.B. Lawson, D. Jancic, P.V. Gejman, A.R. Sanders, P. Holmans, S.L. Slager, D.F. Levinson, and S.P. Hamilton Novel loci for major depression identified by genome-wide association study of Sequenced Treatment Alternatives to Relieve Depression and meta-analysis of three studies Mol. Psychiatry 16 2011 202 215
379. R.D. Shytle, A.A. Silver, K.H. Sheehan, D.V. Sheehan, and P.R. Sanberg Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine Depress. Anxiety 16 2002 89 92
380. N. Singewald, C. Sinner, A. Hetzenauer, S.B. Sartori, and H. Murck Magnesium-deficient diet alters depression- and anxiety-related behavior in mice - influence of desipramine and Hypericum perforatum extract Neuropharmacology 47 2004 1189 1197
381. M. Siwek, D. Dudek, I.A. Paul, M. Sowa-Kucma, A. Zieba, P. Popik, A. Pilc, and G. Nowak Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study J. Affect. Disord. 118 2009 187 195
382. P. Skolnick, P. Popik, and R. Trullas Glutamate-based antidepressants: 20 years on Trends Pharmacol. Sci. 30 2009 563 569
383. G. Skuza, and Z. Rogoz A potential antidepressant activity of SA4503, a selective sigma(1) receptor agonist Behav. Pharmacol. 13 2002 537 543
384. G. Skuza, and Z. Rogoz Antidepressant-like effect of PRE-084, a selective sigma1 receptor agonist, in Albino Swiss and C57BL/6J mice Pharmacol. Rep. 61 2009 1179 1183
385. D.A. Slattery, S. Desrayaud, and J.F. Cryan GABAB receptor antagonist-mediated antidepressant-like behavior is serotonin-dependent J. Pharmacol. Exp. Ther. 312 2005 290 296
386. D.A. Slattery, A.L. Hudson, and D.J. Nutt Invited review: the evolution of antidepressant mechanisms Fundam. Clin. Pharmacol. 18 2004 1 21
387. A. Sluzewska, M. Sobieska, and J.K. Rybakowski Changes in acute-phase proteins during lithium potentiation of antidepressants in refractory depression Neuropsychobiology 35 1997 123 127
388. J.K. Soczynska, R.B. Mansur, E. Brietzke, W. Swardfager, S.H. Kennedy, H.O. Woldeyohannes, A.M. Powell, M.S. Manierka, and R.S. McIntyre Novel therapeutic targets in depression: minocycline as a candidate treatment Behav. Brain Res. 235 2012 302 317
389. C. Song, and H. Wang Cytokines mediated inflammation and decreased neurogenesis in animal models of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 35 2011 760 768
390. P. Soronen, O. Mantere, T. Melartin, K. Suominen, M. Vuorilehto, H. Rytsala, P. Arvilommi, I. Holma, M. Holma, P. Jylha, H.M. Valtonen, J. Haukka, E. Isometsa, and T. Paunio P2RX7 gene is associated consistently with mood disorders and predicts clinical outcome in three clinical cohorts Am. J. Med. Genet. B 156B 2011 435 447
391. S.J. Spencer, L. Xu, M.A. Clarke, M. Lemus, A. Reichenbach, B. Geenen, T. Kozicz, and Z.B. Andrews Ghrelin regulates the hypothalamic-pituitary-adrenal axis and restricts anxiety after acute stress Biol. Psychiatry 72 2012 457 465
392. B. Sperlagh, C. Csolle, R.D. Ando, F. Goloncser, A. Kittel, and M. Baranyi The role of purinergic signaling in depressive disorders Neuropsychopharmacol. Hungarica: Magyar Pszichofarmakologiai Egyesulet lapja - Off. J. Hungarian Assoc. Psychopharmacol. 14 2012 231 238
393. V. Srinivasan, D. De Berardis, S.D. Shillcutt, and A. Brzezinski Role of melatonin in mood disorders and the antidepressant effects of agomelatine Expert Opin. Investig. Drugs 21 2012 1503 1522
394. T.J. Stamm, M. Adli, J. Kirchheiner, M.N. Smolka, R. Kaiser, P.B. Tremblay, and M. Bauer Serotonin transporter gene and response to lithium augmentation in depression Psychiatr. Genet. 18 2008 92 97
395. R. Steinberg, R. Alonso, G. Griebel, L. Bert, M. Jung, F. Oury-Donat, M. Poncelet, C. Gueudet, C. Desvignes, G. Le Fur, and P. Soubrie Selective blockade of neurokinin-2 receptors produces antidepressant-like effects associated with reduced corticotropin-releasing factor function J. Pharmacol. Exp. Ther. 299 2001 449 458
396. C.A. Stockmeier, X. Shi, L. Konick, J.C. Overholser, G. Jurjus, H.Y. Meltzer, L. Friedman, P. Blier, and G. Rajkowska Neurokinin-1 receptors are decreased in major depressive disorder Neuroreport 13 2002 1223 1227
397. T.P. Su, E.D. London, and J.H. Jaffe Steroid binding at sigma-receptors suggests a link between endocrine, nervous, and immune-systems Science 240 1988 219 221
398. N. Sudo, Y. Chida, Y. Aiba, J. Sonoda, N. Oyama, X.N. Yu, C. Kubo, and Y. Koga Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice J. Physiol. 558 2004 263 275
399. C.J. Swanson, T.P. Blackburn, X. Zhang, K. Zheng, Z.Q. Xu, T. Hokfelt, T.D. Wolinsky, M.J. Konkel, H. Chen, H. Zhong, M.W. Walker, D.A. Craig, C.P. Gerald, and T.A. Branchek Anxiolytic- and antidepressant-like profiles of the galanin-3 receptor (Gal3) antagonists SNAP 37889 and SNAP 398299 Proc. Natl. Acad. Sci. USA 102 2005 17489 17494
400. B. Szewczyk, E. Poleszak, M. Sowa-Kucma, M. Siwek, D. Dudek, B. Ryszewska-Pokrasniewicz, M. Radziwon-Zaleska, W. Opoka, J. Czekaj, A. Pilc, and G. Nowak Antidepressant activity of zinc and magnesium in view of the current hypotheses of antidepressant action Pharmacol. Rep. 60 2008 588 589
401. K. Takamori, N. Kawashima, S. Chaki, A. Nakazato, and K. Kameo Involvement of the hypothalamus-pituitary-adrenal axis in antidepressant activity of corticotropin-releasing factor subtype 1 receptor antagonists in the rat learned helplessness test Pharmacol. Biochem. Behav. 69 2001 445 449
402. M. Takebayashi, A. Kagaya, Y. Uchitomi, A. Kugaya, M. Muraoka, N. Yokota, J. Horiguchi, and S. Yamawaki Plasma dehydroepiandrosterone sulfate in unipolar major depression. Short communication J. Neural Transm. 105 1998 537 542
403. A. Tanti, and C. Belzung Neurogenesis along the septo-temporal axis of the hippocampus: are depression and the action of antidepressants region-specific? Neuroscience 252 2013 234 252
404. P. Tejedor-Real, J.A. Mico, C. Smadja, R. Maldonado, B.P. Roques, and J. Gilbert-Rahola Involvement of delta-opioid receptors in the effects induced by endogenous enkephalins on learned helplessness model Eur. J. Pharmacol. 354 1998 1 7
405. M.M. Torregrossa, E.M. Jutkiewicz, H.I. Mosberg, G. Balboni, S.J. Watson, and J.H. Woods Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats Brain Res. 1069 2006 172 181
406. P. Tran, P. Skolnick, P. Czobor, N.Y. Huang, M. Bradshaw, A. McKinney, and M. Fava Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial J. Psychiatr. Res. 46 2012 64 71
407. M.H. Trivedi, A.J. Rush, S.R. Wisniewski, A.A. Nierenberg, D. Warden, L. Ritz, G. Norquist, R.H. Howland, B. Lebowitz, P.J. McGrath, K. Shores-Wilson, M.M. Biggs, G.K. Balasubramani, M. Fava, and S.S. Team Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice Am. J. Psychiatry 163 2006 28 40
408. R. Trullas, and P. Skolnick Functional antagonists at the Nmda receptor complex exhibit antidepressant actions Eur. J. Pharmacol. 185 1990 1 10
409. N. Tsankova, W. Renthal, A. Kumar, and E.J. Nestler Epigenetic regulation in psychiatric disorders Nat. Rev. Neurosci. 8 2007 355 367
410. N.M. Tsankova, O. Berton, W. Renthal, A. Kumar, R.L. Neve, and E.J. Nestler Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action Nat. Neurosci. 9 2006 519 525
411. A. Tschenett, N. Singewald, M. Carli, C. Balducci, P. Salchner, A. Vezzani, H. Herzog, and G. Sperk Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors Eur. J. Neurosci. 18 2003 143 148
412. J.C. Tu, B. Xiao, S. Naisbitt, J.P. Yuan, R.S. Petralia, P. Brakeman, A. Doan, V.K. Aakalu, A.A. Lanahan, M. Sheng, and P.F. Worley Coupling of mGluR/Homer and PSD-95 complexes by the shank family of postsynaptic density proteins Neuron 23 1999 583 592
413. J.R. Turner, L.M. Castellano, and J.A. Blendy Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior J. Pharmacol. Exp. Ther. 334 2010 665 672
414. S. Uchida, K. Hara, A. Kobayashi, H. Funato, T. Hobara, K. Otsuki, H. Yamagata, B.S. McEwen, and Y. Watanabe Early life stress enhances behavioral vulnerability to stress through the activation of REST4-mediated gene transcription in the medial prefrontal cortex of rodents J. Neurosci. 30 2010 15007 15018
415. M. Udina, P. Castellvi, J. Moreno-Espana, R. Navines, M. Valdes, X. Forns, K. Langohr, R. Sola, E. Vieta, and R. Martin-Santos Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis J. Clin. Psychiatry 73 2012 1128 1138
416. M. Ukai, H. Maeda, Y. Nanya, T. Kameyama, and K. Matsuno Beneficial effects of acute and repeated administrations of sigma receptor agonists on behavioral despair in mice exposed to tail suspension Pharmacol. Biochem. Behav. 61 1998 247 252
417. A. Urani, F.J. Roman, V.L. Phan, T.P. Su, and T. Maurice The antidepressant-like effect induced by sigma(1)-receptor agonists and neuroactive steroids in mice submitted to the forced swimming test J. Pharmacol. Exp. Ther. 298 2001 1269 1279
418. W. Vale, J. Spiess, C. Rivier, and J. Rivier Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin Science 213 1981 1394 1397
419. A. Vant Veer, and W.A. Carlezon Jr. Role of kappa-opioid receptors in stress and anxiety-related behavior Psychopharmacology (Berl.) 229 2013 435 452
420. C.D. van der Velde Rapid clinical effectiveness of MIF-I in the treatment of major depressive illness Peptides 4 1983 297 300
421. R. Vergura, G. Balboni, B. Spagnolo, E. Gavioli, D.G. Lambert, J. McDonald, C. Trapella, L.H. Lazarus, D. Regoli, R. Guerrini, S. Salvadori, and G. Calo Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist Peptides 29 2008 93 103
422. B. Voleti, A. Navarria, R.J. Liu, M. Banasr, N. Li, R. Terwilliger, G. Sanacora, T. Eid, G. Aghajanian, and R.S. Duman Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses Biol. Psychiatry 74 2013 742 749
423. C. Wahlestedt, E.M. Pich, G.F. Koob, F. Yee, and M. Heilig Modulation of anxiety and Neuropeptide-Y-Y1 receptors by antisense oligodeoxynucleotides Science 259 1993 528 531
424. A.K. Walker, P.D. Rivera, Q. Wang, J.C. Chuang, S. Tran, S. Osborne-Lawrence, S.J. Estill, R. Starwalt, P. Huntington, L. Morlock, J. Naidoo, N.S. Williams, J.M. Ready, A.J. Eisch, A.A. Pieper, and J.M. Zigman The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis Mol. Psychiatry 2014, http://dx.doi.org/10.1038/mp.2014.34, in press
425. J.J. Wang, A.L. Mack, A. Coop, and R.R. Matsumoto Novel sigma (sigma) receptor agonists produce antidepressant-like effects in mice Eur. Neuropsychopharmacol. 17 2007 708 716
426. J.S. Wang, H.J. Zhu, J.S. Markowitz, J.L. Donovan, and C.L. DeVane Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein Psychopharmacology (Berl.) 187 2006 415 423
427. Y. Wang, F. Yang, Y.F. Liu, F. Gao, and W. Jiang Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats Neurosci. Lett. 499 2011 74 79
428. D. Warden, A.J. Rush, M.H. Trivedi, M. Fava, and S.R. Wisniewski The STAR∗D Project results: a comprehensive review of findings Curr. Psychiatry Rep. 9 2007 449 459
429. J.L. Warner-Schmidt, and R.S. Duman VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants Proc. Natl. Acad. Sci. USA 104 2007 4647 4652
430. N. Whittle, G. Lubec, and N. Singewald Zinc deficiency induces enhanced depression-like behaviour and altered limbic activation reversed by antidepressant treatment in mice Amino Acids 36 2009 147 158
431. E. Widerlov, L.H. Lindstrom, C. Wahlestedt, and R. Ekman Neuropeptide-Y and Peptide-Yy as possible cerebrospinal-fluid markers for major depression and schizophrenia, respectively J. Psychiatr. Res. 22 1988 69 79
432. S.M. Wilkinson, H. Gunosewoyo, M.L. Barron, A. Boucher, M. McDonnell, P. Turner, D.E. Morrison, M.R. Bennett, I.S. McGregor, L.M. Rendina, and M. Kassiou The first CNS-active carborane: a novel P2X receptor antagonist with antidepressant activity ACS Chem. Neurosci. 5 5 2014 335 339
433. A. Wojcicka, J.H. Bassett, and G.R. Williams Mechanisms of action of thyroid hormones in the skeleton Biochim. Biophys. Acta 1830 2013 3979 3986
434. Y. Xu, H. Liu, F. Li, N. Sun, Y. Ren, Z. Liu, X. Cao, Y. Wang, P. Liu, and K. Zhang A polymorphism in the microRNA-30e precursor associated with major depressive disorder risk and P300 waveform J. Affect. Disord. 127 2010 332 336
435. T. Yoshimizu, T. Shimazaki, A. Ito, and S. Chaki An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats Psychopharmacology (Berl.) 186 2006 587 593
436. C.A. Zarate Jr., N.E. Brutsche, L. Ibrahim, J. Franco-Chaves, N. Diazgranados, A. Cravchik, J. Selter, C.A. Marquardt, V. Liberty, and D.A. Luckenbaugh Replication of ketamines antidepressant efficacy in bipolar depression: a randomized controlled add-on trial Biol. Psychiatry 71 2012 939 946
437. C.A. Zarate Jr., D. Mathews, L. Ibrahim, J.F. Chaves, C. Marquardt, I. Ukoh, L. Jolkovsky, N.E. Brutsche, M.A. Smith, and D.A. Luckenbaugh A randomized trial of a low-trapping nonselective N-methyl-d-aspartate channel blocker in major depression Biol. Psychiatry 74 2013 257 264
438. C.A. Zarate Jr., J.B. Singh, P.J. Carlson, N.E. Brutsche, R. Ameli, D.A. Luckenbaugh, D.S. Charney, and H.K. Manji A randomized trial of an N-methyl-d-aspartate antagonist in treatment-resistant major depression Arch. Gen. Psychiatry 63 2006 856 864
439. C.A. Zarate Jr., J.B. Singh, J.A. Quiroz, G. De Jesus, K.K. Denicoff, D.A. Luckenbaugh, H.K. Manji, and D.S. Charney A double-blind, placebo-controlled study of memantine in the treatment of major depression Am. J. Psychiatry 163 2006 153 155
440. C.A. Zarate, J.L. Payne, J. Quiroz, J. Sporn, K.K. Denicoff, D. Luckenbaugh, D.S. Charney, and H.K. Manji An open-label trial of riluzole in patients with treatment-resistant major depression Am. J. Psychiatry 161 2004 171 174
441. R. Zhou, P. Yuan, Y. Wang, J.G. Hunsberger, A. Elkahloun, Y. Wei, P. Damschroder-Williams, J. Du, G. Chen, and H.K. Manji Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 34 2009 1395 1405
442. H.J. Zhu, J.S. Wang, J.S. Markowitz, J.L. Donovan, B.B. Gibson, and C.L. DeVane Risperidone and paliperidone inhibit p-glycoprotein activity in vitro Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol. 32 2007 757 764
443. A.W. Zobel, T. Nickel, H.E. Kunzel, N. Ackl, A. Sonntag, M. Ising, and F. Holsboer Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated J. Psychiatr. Res. 34 2000 171 181
444. C.F. Zorumski, S.M. Paul, Y. Izumi, D.F. Covey, and S. Mennerick Neurosteroids, stress and depression: potential therapeutic opportunities Neurosci. Biobehav. Rev. 37 2013 109 122